NYSE:DHRLife Sciences
How Fresh Analyst Optimism On Bioprocessing At Danaher (DHR) Has Changed Its Investment Story
Earlier this week, Goldman Sachs initiated coverage on Danaher Corporation with a Buy rating, while KeyBanc Capital Markets reiterated upbeat views on the company’s bioprocessing and life sciences exposure.
Together, these opinions point to renewed confidence that Danaher’s bioprocessing franchise and conservative guidance could benefit from improving biotech funding trends.
We’ll now examine how this renewed focus on Danaher’s bioprocessing strength may influence the company’s existing...